Evidence map›Paper›PMID 42782037›Full record

ArticleJACC. Case reports2026

Coexistence of Hypertrophic Cardiomyopathy and Hereditary Transthyretin Amyloid Cardiomyopathy.

Roxanne Coderre, Gregorio Tersalvi, Rosalyn O Adigun, Barry A Boilson, Daniel D Borgeson, Alfredo L Clavell, Ian C Chang, Angela Dispenzieri, Martha Grogan, Omar F AbouEzzeddine

Abstract readCase Reports
In one paragraph

Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Roxanne CoderreDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Gregorio TersalviDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Rosalyn O AdigunDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Barry A BoilsonDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Daniel D BorgesonDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Alfredo L ClavellDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Ian C ChangDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Angela DispenzieriDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Martha GroganDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Omar F AbouEzzeddineDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: abouezzeddine.omar@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLeft ventricular wall thickening may result from disease such as hypertrophic cardiomyopathy (HCM) or infiltrative cardiomyopathies such as transthyretin amyloidosis (ATTR). When features of both conditions coexist, distinguishing the dominant pathology can be challenging and may influence management. CASE SUMMARY: A 72-year-old man presented with progressive exertional dyspnea and syncope. He was found to have severe left ventricular outflow tract obstruction with systolic anterior motion of the mitral valve. He experienced marked symptomatic improvement after initiation of mavacamten for presumed HCM. Genetic testing later revealed a pathogenic TTR p.Val50Met variant, and technetium-99m pyrophosphate scintigraphy demonstrated grade 3 myocardial uptake consistent with hereditary ATTR cardiomyopathy. Persistent symptoms led to septal myectomy, which demonstrated marked myocyte hypertrophy and moderate myocardial amyloid deposition but insufficient infiltration to explain the hypertrophy. DISCUSSION: This case highlights the diagnostic complexity of coexisting HCM and hereditary ATTR cardiomyopathy and underscores the importance of multimodality imaging, genetic testing, and pathologic correlation. TAKE-HOME MESSAGES: Dynamic left ventricular outflow tract obstruction does not exclude cardiac amyloidosis. Dual cardiomyopathies should be considered when clinical, imaging, and genetic findings appear discordant.

Indexed as

echocardiographygeneticsmurmurpreserved ejection fraction

Identifiers

PMID42782037
PMCPMC13616533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.